# Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

> **NCT06567769** · PHASE1 · RECRUITING · sponsor: **GC Biopharma Corp** · enrollment: 9 (estimated)

## Conditions studied

- Sanfilippo Syndrome Type A

## Interventions

- **DRUG:** GC1130A

## Key facts

- **NCT ID:** NCT06567769
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567769, "Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06567769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*